Malignant prolactinoma: case report and review of the literature

被引:48
作者
Kars, Marleen [1 ]
Roelfsema, Ferdinand [1 ]
Romijn, Johannes A. [1 ]
Pereira, Alberto M. [1 ]
机构
[1] Leiden Univ, Ctr Med, Dept Endocrinol, NL-2300 RC Leiden, Netherlands
关键词
D O I
10.1530/eje.1.02268
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pituitary carcinomas are extremely rare. In general, the initial clinical, biochemical, and histological characteristics are of minimal utility in distinguishing benign adenomas from pituitary carcinomas. We describe a 63-year-old woman with a macroprolactinoma, who presented with diplopia and blurred vision. This unusual initial presentation and the subsequent aggressive clinical course, with diffuse local and distant intramedulary metastases, prompted us in retrospect to make a detailed analysis of the therapeutic interventions and histology. In addition, we reviewed all available literature on published cases of malignant prolactinoma and detailed their epidemiological, clinical, and histopathological characteristics. In brief, it is postulated that pituitary carcinomas arise from the transformation of initially large, but benign, adenomas. Unusual and/or atypical clinical manifestations appear to occur more frequently. In vivo, the development of dopamine agonist resistance in invasive macroprolactinoma is indicative of malignancy and should prompt the clinician to perform a biopsy of the tumor. For pituitary tumors that exhibit high mitotic activity, increased Ki67 and/or p53 immunoreactivity, it may be useful to denote these tumors as 'atypical' prolactinomas to raise the possibility of future malignant development.
引用
收藏
页码:523 / 534
页数:12
相关论文
共 51 条
[1]  
Arias M, 2000, An Med Interna, V17, P192
[2]   INTRACRANIAL DISSEMINATION OF A MACROPROLACTINOMA [J].
ASSIES, J ;
VERHOEFF, NPLG ;
BOSCH, DA ;
HOFLAND, LJ .
CLINICAL ENDOCRINOLOGY, 1993, 38 (05) :539-546
[3]  
ATIENZA DM, 1991, CANCER, V68, P1605, DOI 10.1002/1097-0142(19911001)68:7<1605::AID-CNCR2820680723>3.0.CO
[4]  
2-D
[5]  
Bayindir C, 1997, BRIT J NEUROSURG, V11, P350
[6]   MALIGNANT PROLACTINOMA [J].
BEREZIN, M ;
GUTMAN, I ;
TADMOR, R ;
HOROWITZ, A ;
FINDLER, G .
ACTA ENDOCRINOLOGICA, 1992, 127 (05) :476-480
[7]   AN INTRACRANIAL METASTASIS FROM A PRL SECRETING PITUITARY-TUMOR [J].
COHEN, DL ;
DIENGDOH, JV ;
THOMAS, DGT ;
HIMSWORTH, RL .
CLINICAL ENDOCRINOLOGY, 1983, 18 (03) :259-264
[8]   Metastatic prolactinoma - Case report with immunohistochemical assessment for p53 and ki-67 antigens [J].
Crusius, PS ;
Forcelini, CM ;
Mallmann, AB ;
Silveira, DA ;
Lersch, E ;
Seibert, CA ;
Crusius, MU ;
Carazzo, CA ;
Crusius, CU ;
Goellner, E .
ARQUIVOS DE NEURO-PSIQUIATRIA, 2005, 63 (3B) :864-869
[9]   Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas [J].
de Herder, WW ;
Reijs, AEM ;
de Swart, J ;
Kaandorp, Y ;
Lamberts, SWJ ;
Krenning, EP ;
Kwekkeboom, DJ .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (01) :46-50
[10]  
FIGARELLABRANGE.D, 1992, ENDOCR PATHOL, V3, pS11